

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Boan Biotech**  
**博安生物**

**Shandong Boan Biotechnology Co., Ltd.**

**山东博安生物技术股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6955)**

## **VOLUNTARY ANNOUNCEMENT**

### **THE COMPANY HAS OBTAINED GMP CERTIFICATION FOR BOYUNO® FROM THE BRAZILIAN AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA**

The board of directors (the “**Board**”) of Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) announces that its biological product, Boyuno® (Bevacizumab Injection), received GMP certification from the Brazilian Agência Nacional de Vigilância Sanitária (“**ANVISA**”). This GMP certification covers the drug substance and drug product of Boyuno®.

Boyuno® is a recombinant anti-VEGF humanized monoclonal antibody injection, independently developed by the Company as a biosimilar to bevacizumab. As the Company’s first in-house developed commercial product, Boyuno® was launched in China in 2021 for the treatment of multiple types of cancer including advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), metastatic colorectal cancer, ovarian cancer and cervical cancer. Since its launch in China, Boyuno® has been widely recognized by healthcare professionals and patients for its efficacy and safety. In April 2023, ANVISA officially accepted the Biologics License Application (BLA) for Boyuno® in Brazil.

ANVISA is a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). The Company’s comprehensive management system in research and development, production, and quality control, built to the highest international standards, ensured that this inspection was passed with no observations. Obtaining the GMP certification from ANVISA has advanced the marketing authorization approval of Boyuno® in Brazil, and also established a solid quality foundation for the global commercial reach of the Company’s future innovative biologics and biosimilar products.

The Company believes that the introduction of Boyuno® in the Brazilian market will increase the accessibility of bevacizumab to more local patients, thus improving their survival and the quality of life.

## **ABOUT THE BRAZILIAN MARKET**

The Brazilian pharmaceutical market is a major emerging market with huge growth potential. According to data from IQVIA, the size of the pharmaceutical market in Brazil in 2022 was approximately USD30.2 billion, accounting for about half of the entire Latin American pharmaceutical market, and it is expected to maintain an annual growth rate of 7-10% from 2023 to 2027.

In terms of the needs of local patients, according to data from the International Agency for Research on Cancer of the World Health Organization, breast cancer, lung cancer, colorectal cancer, and cervical cancer were among the top ten cancers in terms of new cases in Brazil in 2020, indicating huge unmet treatment needs in the country. Bevacizumab, a preferred anti-angiogenic therapy, is widely used to treat various malignancies, including the aforementioned types of cancer.

By Order of the Board  
**Shandong Boan Biotechnology Co., Ltd.**  
**Jiang Hua**

*Chairlady, Chief Executive Officer and Executive Director*

Yantai, the People's Republic of China, 17 January 2024

*As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Dr. Dou Changlin; the non-executive directors of the Company are Mr. Liu Yuanchong and Ms. Li Li; and the independent non-executive directors of the Company are Mr. Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.*